2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.28 Cuestra Camunas

PP01.28 Cuestra Camunas - Abstract

Pdf Summary

A systematic review and meta-analysis examined PD-L1 expression as a biomarker for pathologic response in patients receiving neoadjuvant PD-1 monotherapy and chemoimmunotherapy (chemoIO) for resectable non-small cell lung cancer (NSCLC). The study included data from 29 prospective trials with 2094 patients, comparing treatment outcomes based on PD-L1 expression levels. Results showed that PD-L1 expression influenced both pathologic complete response (pCR) and major pathologic response (MPR) rates. Patients with higher PD-L1 expression levels had higher MPR rates, with chemoIO showing numerically higher pCR/MPR rates across all PD-L1 subgroups compared to PD-1 monotherapy. The study indicated significant impacts of treatment regimen and PD-L1 expression on pCR rates. However, the interaction between regimen and PD-L1 expression did not significantly affect outcomes between chemoIO and PD-1 monotherapy. The findings suggest that PD-L1 expression can serve as a useful biomarker in predicting treatment response in early-stage NSCLC patients undergoing neoadjuvant therapy. Future research will focus on evaluating the association between PD-L1 expression and recurrence data for these treatment regimens.

Keywords

PD-L1 expression

pathologic response

neoadjuvant therapy

non-small cell lung cancer

PD-1 monotherapy

chemoimmunotherapy

treatment outcomes

pathologic complete response

major pathologic response

early-stage NSCLC